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Abstract 
Objectives 
Oral dysesthesia (burning mouth syndrome) is characterised by a burning-like 
sensation of the oral mucosa. The aetiology of this disorder is still unknown, 
however associations with oral fungal carriage have been proposed and applied 
clinically. The aim of the this study was to compare oral Candida carriage in 
patients with oral dysesthesia with Candida carriage in patients with other 
commonly diagnosed oral diseases to clarify the relationship between Candida 
and oral dysesthesia. 
Subjects and Methods 
441 patients in total including 79 patients diagnosed with oral dysesthesia were 
included in this study. A retrospective analysis of mycological investigations 
undertaken in patients with clinically diagnosed oral dysesthesia compared with 
other oral conditions was undertaken. 
Results 
Oral carriage of Candida was found in 63.3% (50 of 79) of patients with oral 
dysesthesia. The frequency of carriage, and oral load of Candida were not 
significantly increased in patients with oral dysesthesia relative to the other 
conditions assessed. Patients with clinical signs of fungal infection or xerostomia 
presented with increased carriage of Candida. 
Conclusion 
There is no association between oral dysesthesia and the presence or load of 
oral Candida.  
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Introduction   
Oral dysesthesia (OD), also known as Burning Mouth Syndrome (BMS), is a 
chronic orofacial pain condition that is associated with moderate to intense pain 
of a burning or similar nature, which affects the oral mucosa 1,2. Patients affected 
by this condition may suffer disruption to normal social relationships and a 
general diminution in quality of life 3,4. The International Association for the Study 
of Pain, International Headache Society and other recent literature have provided 
classification and diagnostic criteria for BMS that may be applied in both clinical 
and research settings (Table 1) 5-8. 
 
BMS typically affects women more frequently than men at a female to male ratio 
of approximately 3:1 2. The majority of affected individuals are over 50 years of 
age and the post-menopausal period of life is frequently implicated 9,10. The 
prevalence of BMS is estimated to be between 0.7% and 4.5% based on different 
sample populations and inclusion criteria 9-13. The lack of strict protocols for 
clinical and serological examination of patients to differentiate between BMS and 
other diseases associated with painful intra-oral mucosal symptoms continues to 
hinder a sound epidemiological understanding of BMS being established from 
existing research 2,10. 
 
The aetiopathogenesis of OD principally reflects psychological factors, and a 
number of systemic (e.g. diabetes mellitus) and local factors have all been 
suggested to be related to symptoms 2. Infection by Candida albicans continues 
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to be quoted as a possible cause but there are no consistent supportive data 14-
17. As Candida is a commensal, it might be expected to frequently give rise to 
oral mucosal discomfort in patients at risk of candidal overgrowth, but not other 
conditions. 
 
Reports of Candida oral carriage rates among BMS patients range from 25% to 
93.7% within the published literature 14-16,18-23. Three independent studies have 
shown no statistically significant difference in the rate of Candida carriage 
between BMS and control subjects 18,19,23. A recent Japanese study found no 
significant difference between the oral carriage of Candida among BMS patients 
compared with xerostomia or dysgeusia 18. Comparison of the Candida carriage 
of BMS patients relative to other oral diseases may yield further vital evidence to 
support or deny an association.  
 
The aim of this research was to investigate the relationship between Candida and 
OD by examining the presentation, frequency and oral load of Candida in 
patients with a variety of oral diseases. The inclusion of a large cohort, 
assessment of a national population that has not been previously studied in this 
field, and comparison of a wide range of oral disease states are unique aspects 
of this study that are likely to provide a deeper understanding of the association 
between Candida and the presence of abnormal oral signs and symptoms.  
 
Materials and Methods 
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The study constituted an audit of records for a convenience sample of 441 
patients who had a variety of oral mucosal and non-mucosal diseases, including 
burning mouth syndrome, atypical facial pain, oral candidosis, angular stomatitis, 
Candida-associated denture induced stomatitis, geographic tongue, hyperplasia, 
oral epithelial dysplasia, oral squamous cell carcinoma, recurrent aphthous 
ulceration, xerostomia, oral lichen planus, pemphigus vulgaris and mucous 
membrane pemphigoid; the diagnoses being based upon clinical features alone. 
The study cohort included 277 females and 164 males. The mean age of patients 
participating in the study was 54.7 years, with a range extending from 4.4 to 88.7 
years of age. Further details of demographics are provided in Table 2.  
 
All patients were attendees of the Oral Medicine Clinic of the UCL Eastman 
Dental Hospital, London, United Kingdom. Patient consent was obtained for 
clinical oral examination, oral rinse collection and evaluation of yeast growth. All 
patients underwent microbiological estimation of oral Candida carriage as part of 
their standard of care routine clinical work up during a period of two years 
(between 1993-1995) when this diagnostic service was available to resident 
clinicians. Patients were required to swill 10 ml of sterile distilled water around 
the mouth for 60 seconds before expectorating into a sterile specimen container. 
1 ml of this sample was cultured on Sabouraud's dextrose agar (Sigma-Aldrich, 
Poole, UK) containing chloramphenicol (1 mg/l; Sigma-Aldrich). Colony forming 
units (cfu) per ml of mouth swill were calculated. 
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Isolates were defined to the species level by phenotypic methods. A germ-tube 
test (GTT) [presence of germ tubes after growth in horse serum (Sigma-Aldrich) 
for 90 min at 37°C] gave a positive identification for C. albicans or C. 
dubliniensis. 
The clinical and laboratory data were collated through a record audit to assess 
the comparative effects that different diseases may have on the presence of 
Candida species and the oral load of Candida within the oral cavity. Statistical 
analyses were performed with GraphPad Prism Version 4.01 (GraphPad Inc, San 
Diego, CA, USA). The Wilcoxon rank-sum test and Fisher’s exact test were used 
to determine the difference in Candida load and presence respectively between 
different disease groups.  A probability (p) of less than or equal to 0.05 was set 
as an indication of statistically significant variations.  
 
Results 
Frequency of oral carriage of Candida species 
Oral carriage of Candida was found in 63.3% (50 of 79) of patients with OD.  
Candida species were found in 90.9% of individuals with xerostomia (20 of 22). 
Patients with clinical signs of Candida infection (denture induced stomatitis or 
candidosis/angular cheilitis) showed the presence of Candida species in 84.4% 
(38 of 45) and 83.9% (73 of 87) of cases respectively. A diagnosis of hyperplasia 
/dysplasia/squamous cell carcinoma was associated with Candida in 71.9% (41 
of 57) of patients. Patients with mucocutaneous disease (oral lichen 
planus/pemphigus vulgaris/mucous membrane pemphigoid) and RAS presented 
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with Candida in 59.7% (43 of 72) and 56.3% (18 of 32) of patients. 57.1% (16 of 
28) of patients with geographic tongue carried Candida species (Table 3).  
 
 
Statistical analysis of the frequency of Candida carriage among the subgroups 
showed no significant differences (P<0.05) with exception of the subgroups of 
patients diagnosed with xerostomia, Candida-associated denture induced 
stomatitis and candidosis/angular cheilitis. The oral load of Candida species was 
significantly higher in these three groups relative to BMS patients. 
 
 
Candida load  
The mean count of Candida in individuals with BMS was 4,705 cfu (range from 0 
– 52,000 cfu). The mean oral load of Candida among xerostomia patients was 
9,175 (range from 0 – 45,300 cfu). Patients with clinical signs of Candida 
infection (denture induced stomatitis/candidosis/angular cheilitis) showed the 
mean count of Candida to be 8,920 (range from 0 – 67,000 cfu) and 8,197 (range 
from 0 – 121,000 cfu) respectively. A diagnosis of 
hyperplasia/dysplasia/squamous cell carcinoma was associated with a mean 
Candida count of 3,448 (range from 0 – 45,000 cfu). Mucocutaneous disease 
(oral lichen planus/pemphigus vulgaris/mucous membrane pemphigoid) and RAS 
were associated with the mean Candida count of 2,506   (range from 0 – 40,000 
cfu) and 1,216 (range from 0 – 10,000 cfu).  
 
Statistical analysis of the Candida counts among the subgroups showed no 
significant differences (P<0.05) with the exception of the subgroups of patients 
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diagnosed with xerostomia, denture induced stomatitis and candidosis/angular 
cheilitis. The oral load of Candida species was significantly higher in these three 
groups when compared with the BMS patient group (Table 3). 
 
Discussion 
 
The results of this paper support the hypothesis that there is no association 
between the presence or load of Candida and the diagnosis of burning mouth 
syndrome/oral dysesthesia. This assertion is made on the basis that Candida 
carriage was not found to be significantly higher among patients with BMS 
than the other oral diseases assessed. 
 
The frequency of carriage of Candida species in the present group of patients 
was 63.3%. Previous studies have reported that 25% to 93.7% of patients with 
BMS may carry Candida 14-16,18-23, however it is critical to note that most 
show that the frequency of carriage among BMS patients is not significantly 
greater than in control groups 18,19,23. Indeed, 70% or more of healthy patients 
may harbor Candida species in the mouth 24. 
 
BMS patients within this study did not exhibit a significantly higher prevalence or 
load of Candida than any other oral disease examined. The oral carriage of 
Candida among patients with BMS was in fact found to be significantly lower than 
in patients diagnosed with xerostomia, Candida-associated denture induced 
stomatitis and candidosis/angular cheilitis. The significantly higher carriage of 
Candida species observed in patients with clinical signs of Candida infection 
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(denture induced stomatitis, candidosis/angular cheilitis) or local 
predisposing factors for increased Candida carriage (xerostomia) would be 
anticipated 18. This finding may be a reassuring indication that the absence 
of association between Candida carriage and BMS demonstrated within 
the data presented is likely to be genuine. Further evidence of consistency is 
suggested by the general similarity in P-value among corresponding conditions 
when examining Candida count and prevalence using separate statistical 
analyses. 
 
An interesting finding within this study is a very high mean level of Candida 
among patients with atypical facial pain. The authors do not believe that this is an 
indicative finding since high outliers in this group skewed the data. Indeed the 
median is considered more representative of the general distribution of load and 
was therefore used in tests for significant differences in Candida prevalence 
among different disease states. 
 
As no detailed Candida typing was undertaken as part of this study, it is 
possible that some of the supposed C. albicans isolates may have been C. 
dubliniensis. It is likely however, that C. albicans was the most common type of 
Candida present, as previous studies of generally well individuals and those with 
BMS have consistently found C. albicans to be the dominant oral yeast 
15,17,19,21,24. 
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The lack of a healthy control group for comparison within this study is a 
weakness that may be counteracted by a strong body of existing research that 
refutes the presence of a significant difference between Candida carriage 
among BMS versus control patients 18,19,23. The data presented confirms 
previous findings that the existence of xerostomia is associated with increased 
Candida presence 18,21. Since no previous research has compared Candida 
carriage among BMS patients with a wide range of alternative oral diseases, 
this unique perspective lends significant weight to the growing body of evidence 
that discredits a microbiological link between Candida infection and BMS.  
 
Such a conclusion also yields important implications for the pharmaceutical 
management of BMS. Topical clonazepam therapy is currently the only 
effective pharmaceutical intervention for BMS that is based on a randomised 
controlled trial 6,25 and is well supported by other studies 26,27. There is 
currently no sound research to support the use of antifungal medication in the 
management of correctly diagnosed BMS 6,20. The findings of this study 
provide further evidence against a microbiological rationale for such an 
approach. 
 
A secondary application of these findings may arise through assessment of 
the diagnostic potential for Candida testing to distinguish between different 
presenting oral diseases. The present results indicate that Candida testing 
may be useful to distinguish between BMS and frank oral candidosis or a 
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predisposing oral environment of xerostomia. However, the clinician must 
balance the information to be gained from this diagnostic procedure against 
considerations of costs, risks and delays in treatment that such a test may 
potentiate. Considering the differentiation potential that a simple clinical 
history, examination and in-chair saliva test may yield, a further probe to 
measure Candida carriage in such circumstances may be diagnostically 
superfluous, despite its potential.  
 
The present results strongly support the notion that Candida is not a local 
factor associated with the aetiology of BMS. Since carriage of Candida among 
BMS patients appears to bear no significant difference to many other oral 
diseases, routine mycological evaluation of patients with likely features of this 
disorder is not warranted and there is no sound microbiological rationale for the 
use of antifungal therapy in the management of BMS. 
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Table 1. Inclusion and exclusion criteria for diagnosis of BMS. 
Inclusion criteria Exclusion criteria 
1) Symptoms of diffuse burning pain 
of the tongue and/or oral mucosa                                    
that may or may not be associated 
with subjective oral dryness and 
loss or alteration of taste or 
sensation. 
2) Burning pain almost every day.  
3) Examination revealing normal 
mucosa in the region of burning. 
4) Absence of systemic disorders or 
laboratory alterations known to be        
associated with orofacial pain. 
1) Presence of specific local etiologic 
evidence for the burning such as 
otherwise defined diseases of the 
oral mucosa or hyposalivation. 
2) Presence of specific systemic 
etiological evidence for the burning 
such as diabetes or anaemia. 
3) Regular use of medications known 
to be associated with oral burning 
and/or alteration of taste or 
sensation. 
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Table 2. Demographics of patients with burning mouth syndrome and other oral mucosal disorders. 
 
Disease group Age (years) Gender 
  
Mean SD Median Min Max Female Male Total Percentage 
 
Burning mouth syndrome 
 
57.9 
 
14.0 
 
58.8 
 
18.4 
 
83.6 
 
60 
 
19 
 
79 
 
17.9% 
          
Atypical facial pain 55.1 18.9 59.1 15.5 80.2 14 5 19 4.3% 
Oral candidosis/angular cheilitis 56.6 15.8 59.2 19.3 84.5 51 36 87 19.7% 
Candida-associated denture induced 
stomatitis 
60.3 14.3 63.0 25.3 82.4 28 17 45 10.2% 
Geographic tongue 46.6 16.6 48.2 11.6 76.8 23 5 28 6.3% 
Hyperplasia/dysplasia/squamous cell 
carcinoma 
51.9 14.0 54.6 24.2 79.8 24 33 57 12.9% 
Recurrent oral ulceration 34.0 14.5 30.4 4.4 74.8 25 7 32 7.2% 
Xerostomia 58.4 14.3 56.5 35.5 85.9 14 8 22 4.9% 
Oral lichen planus/pemphigus 
vulgaris/mucous membrane pemphigoid 
53.3 13.8 53.5 17.3 87.4 38 34 72 16.3% 
All 54.7 16.0 56.8 4.4 88.7 277 164 441  
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Table 3. Candida counts and prevalence compared between burning mouth syndrome and other groups. 
 
 
 
Disease group Candida (count) Candida (prevalence) 
  Mean SD Median Mi
n 
Max P-value Absent Presen
t 
Tota
l 
Percent 
Prevalenc
e 
P-value 
 
Burning mouth syndrome 
 
4,705.2 
 
10,799.8 
 
100 
 
0 
 
52,000 
 
n/a 
 
29 
 
50 
 
79 
 
63.3% 
 
n/a 
              
Atypical facial pain 12,452.6 41,033.5 600 0 180,000 0.677  6 13 19 68.4% 0.793  
Oral candidosis/angular cheilitis 8,197.8 17,880.8 1,000 0 121,000 0.003 * 14 73 87 83.9% 0.003 ** 
Candida-associated denture induced 
stomatitis 
8,920.2 15,737.2 2,000 0 67,000 0.013 * 7 38 45 84.4% 0.014 ** 
Geographic tongue 2,420.0 4,517.0 60 0 16,000 0.567  12 16 28 57.1% 0.361  
Hyperplasia/dysplasia/squamous cell 
carcinoma 
3,448.9 7,413.1 400 0 45,000 0.293  16 41 57 71.9% 0.192  
Recurrent oral ulceration 1,216.3 2,621.7 10 0 10,000 0.492  14 18 32 56.3% 0.524  
Xerostomia 9,175.0 11,807.6 4,000 0 45,300 0.013 * 2 20 22 90.9% 0.017 ** 
Oral lichen planus/pemphigus 
vulgaris/mucous membrane pemphigoid 
2,506.9 6,524.5 90 0 40,000 0.654  29 43 72 59.7% 0.738  
All 7,220.0 30,823.5 460 0 180,000     129 312 441 70.7%     
 
 
 
* significantly higher median count than BMS group (Wilcoxon rank-sum test) 
** significantly higher prevalence than BMS group (Fisher's exact test)   
